The Centers for Disease Control and Prevention (CDC) has updated its guidance to recommend shared clinical decision-making between parents and healthcare providers regarding hepatitis B vaccination for infants born to mothers who test negative for hepatitis B virus. This change allows families to decide whether to vaccinate newborns at birth or to start the vaccination series later in infancy, with the initial dose suggested no earlier than two months of age if deferred at birth [1][2].
For infants born to mothers who test positive for hepatitis B or whose status is unknown, the existing protocol remains unchanged: the hepatitis B vaccine and hepatitis B immune globulin (HBIG) should be administered within 12 hours of birth to protect against perinatal transmission [1][2].
This shared clinical decision-making approach encourages weighing vaccine benefits, potential risks, and infection risks, such as exposure through household contacts or frequent interactions with individuals from regions with high hepatitis B prevalence. Parents are advised to consult healthcare providers about timing and need for vaccination [1][2].
This update is based on evidence showing very low rates of perinatal hepatitis B transmission in the United States, due to effective prenatal screening and prevention measures. ACIP noted the high reliability of prenatal hepatitis B screening, which detects nearly all infections among pregnant women. The changes aim to maintain protections for high-risk infants while providing flexibility for those at lower risk [1].
The CDC is expected to update the child and adolescent immunization schedules in line with these recommendations [1][2]. Coverage for the hepatitis B vaccine under insurance mechanisms, including the Vaccines for Children Program, Medicaid, and the federal Health Insurance Marketplace, will continue consistent with these recommendations [1][2].